Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
6 min read
Obinutuzumab Biologics Sequence Review Report 2026: CD20 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Obinutuzumab, an antibody targeting CD20.
Latest Hotspot
8 min read
ChiCTR2600124230 iPSC derived cardiac muscle cell (Help Therapeutics) Heart Failure Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
ChiCTR2600124230 clinical trial report covering iPSC derived cardiac muscle cell (Help Therapeutics), Phase 3, endpoints, sponsor, geography, readout timing a
Latest Hotspot
8 min read
CTR20261782 Cenerimod Lupus Nephritis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
CTR20261782 clinical trial report covering Cenerimod, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
6 min read
Rituximab Biologics Sequence Review Report 2026: CD20 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Rituximab, an antibody targeting CD20.
Latest Hotspot
8 min read
ChiCTR2600124390 Warfarin Potassium Thrombosis of cerebral veins Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
ChiCTR2600124390 clinical trial report covering Warfarin Potassium, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07577843 Guselkumab/Golimumab Crohn Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07577843 clinical trial report covering Guselkumab/Golimumab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07577856 Guselkumab/Golimumab Colitis, Ulcerative Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07577856 clinical trial report covering Guselkumab/Golimumab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20261803 Savolitinib c-Met positive Stomach Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
CTR20261803 clinical trial report covering Savolitinib, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
6 min read
Ramucirumab Biologics Sequence Review Report 2026: VEGFR-2 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ramucirumab, an antibody targeting VEGFR-2.
Latest Hotspot
8 min read
NCT07578363 Apraclonidine Hydrochloride Eye Redness Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07578363 clinical trial report covering Apraclonidine Hydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07578649 SSGJ-707 MSS/pMMR/MSI-L Endometrial Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07578649 clinical trial report covering SSGJ-707, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
6 min read
Faricimab Biologics Sequence Review Report 2026: VEGF-A/ANG-2 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Faricimab, a bispecific antibody targeting VEGF-A/ANG-2.